SPIKEVAX Dispersion for injection (2021)
Βιβλιογραφική αναφορά
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Περιεχόμενα
1. Name of the medicinal product
Spikevax dispersion for injection. COVID-19 mRNA Vaccine (nucleoside modified).
2. Qualitative and quantitative composition
This is a multidose vial which contains 10 doses of 0.5 mL. One dose (0.5 mL) contains 100 micrograms of messenger RNA (mRNA) (embedded in SM-102 lipid nanoparticles). One dose (0.25 mL) contains 50 micrograms ...
3. Pharmaceutical form
Dispersion for injection. White to off white dispersion (pH: 7.0–8.0).
4.1. Therapeutic indications
Spikevax is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older. The use of this vaccine should be in accordance with official recommendations. ...
4.2. Posology and method of administration
Posology Primary series Individuals 12 years of age and older Spikevax is administered as a course of 2 (two) 100 microgram doses (0.5 mL each). It is recommended to administer the second dose 28 days ...
4.3. Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
4.4. Special warnings and precautions for use
Traceability In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded. Hypersensitivity and anaphylaxis ...
4.5. Interaction with other medicinal products and other forms of interaction
No interaction studies have been performed. Concomitant administration of Spikevax with other vaccines has not been studied.
4.6. Fertility, pregnancy and lactation
Pregnancy There is limited experience with use of Spikevax in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryo/foetal development, parturition ...
4.7. Effects on ability to drive and use machines
Spikevax has no or negligible influence on the ability to drive and use machines. However, some of the effects mentioned under section 4.8 may temporarily affect the ability to drive or use machines. ...
4.8. Undesirable effects
Summary of the safety profile Participants 18 years of age and older The safety of Spikevax was evaluated in an ongoing Phase 3 randomised, placebo-controlled, observer-blind clinical study conducted in ...
4.9. Overdose
No case of overdose has been reported. In the event of overdose, monitoring of vital functions and possible symptomatic treatment is recommended.
5.1. Pharmacodynamic properties
<b>Pharmacotherapeutic group:</b> Vaccine, other viral vaccines <b>ATC code:</b> J07BX03 Mechanism of action Spikevax contains mRNA encapsulated in lipid nanoparticles. The mRNA encodes for the full-length ...
5.2. Pharmacokinetic properties
Not applicable.
5.3. Preclinical safety data
Non-clinical data reveal no special hazard for humans based on conventional studies of repeat dose toxicity and reproductive and developmental toxicity. General toxicity General toxicity studies were conducted ...
6.1. List of excipients
Lipid SM-102 (heptadecan-9-yl 8-{(2-hydroxyethyl)[6-oxo-6-(undecyloxy)hexyl]amino}octanoate) Cholesterol 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) 1,2-Dimyristoyl-rac-glycero-3-methoxypolyethylene ...
6.2. Incompatibilities
This medicinal product must not be mixed with other medicinal products or diluted.
6.3. Shelf life
Unopened vial 7 months at -25ºC to -15ºC. The unopened vaccine may be stored refrigerated at 2°C to 8°C, protected from light, for maximum 30 days. Within this period, up to 12 hours may be used for transportation. ...
6.4. Special precautions for storage
Store frozen between -25ºC to -15ºC. Store in the original carton to protect from light. Do not store on dry ice or below -50ºC. For storage conditions after thawing and first opening see section 6.3. ...
6.5. Nature and contents of container
5 mL dispersion in a vial (type 1 or type 1 equivalent glass) with a stopper (chlorobutyl rubber) and a flip-off plastic cap with seal (aluminium seal). Each vial contains 5 mL. <u>Pack size:</u> 10 multidose ...
6.6. Special precautions for disposal and other handling
The vaccine should be prepared and administered by a trained healthcare professional using aseptic techniques to ensure sterility of the dispersion. The vaccine comes ready to use once thawed. Do not shake ...
7. Marketing authorization holder
MODERNA BIOTECH SPAIN, S.L., Calle Monte Esquinza 30, 28010 Madrid, Spain
8. Marketing authorization number(s)
EU/1/20/1507/001
9. Date of first authorization / renewal of the authorization
Date of first authorisation: 06 January 2021 Date of latest renewal: 04 October 2021
Πηγαίο έγγραφο
Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση: